OGT expands direct sales and support infrastructure in Europe
Oxford, UK – 3rd July 2018. Oxford Gene Technology (OGT), The Molecular Genetics Company, has announced that it is now directly selling Cytocell Fluorescence In Situ Hybridisation (FISH) products through several established affiliates of Sysmex Corporation in Europe following its acquisition last year. The move is a testament to the ongoing successful integration of the two companies and commitment to combine efforts to support and serve end users. Cytocell customers in Poland, Czechia, and Slovakia began benefitting from Sysmex’s established sales and support infrastructure on 1st May, with customers in France, Belgium, Switzerland, and Luxembourg joining them on 1st July, 2018.
As one of the top 10 IVD companies worldwide, Sysmex is well-respected and established in the field of haematology and urinalysis and has a growing focus on life sciences, pathology and personalised medicine. OGT’s Cytocell brand offers the widest range of high-quality, reliable, and cost-effective FISH probes on the market. Cytocell is well known for its comprehensive range, exceptional customer support, service, and expertise. Since the acquisition of OGT by Sysmex last year, the companies have been working hard to develop both commercial and product synergies across their portfolios with a strong focus on growth in molecular diagnostics. OGT is also collaborating with Sysmex to develop an automated FISH testing system, combining OGT’s FISH reagent expertise with Sysmex’s instrumentation technology.
Spencer Howell, Executive VP Sales at OGT, commented, “We’re delighted that our Cytocell customers can now access the benefits of the excellent Sysmex sales and support services in Europe. Sysmex is committed to growing our Cytocell portfolio with new products and by combining its expertise in instrumentation with ours in FISH probe design. Providing our products through the large, experienced, Sysmex sales network and excellent support infrastructure will enable us to grow the business in new areas—namely molecular diagnostics—to provide even more innovative products and solutions for our customers”
OGT anticipates it will also sell its CytoSure™ microarray and SureSeq™ next generation sequencing (NGS) product portfolio through Sysmex in the near future.
For more information please visit www.cytocell.com/contact.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K.
T: +44 (0) 1865 856807; F: +44 (0) 1865 848684
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™ and SureSeq™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. OGT was acquired by Sysmex Corporation (Sysmex), a Japanese in vitrodiagnostic company in June 2017. The acquisition of OGT expands Sysmex’s life science business and reinforces its initiatives towards personalised medicine.
CytoSure™ and SureSeq™: For Research Use Only; Not for Use in Diagnostic Procedures. Cytocell®: Some products may not be available in your region
About Sysmex Corporation
Sysmex Corporation is a world leader in clinical laboratory systemization and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Serving customers for more than 40 years, Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also exploring emerging opportunities in the life science field. Its R&D efforts focus on the development of high-value-added testing and diagnostic technologies that are innovative, original and optimize individual health. Sysmex also seeks to leverage its state-of-the-art technologies for cell, gene and protein analysis. The company, headquartered in Kobe, Japan, has subsidiaries in North America, Latin America, Europe, the Middle East, Africa, China and Asia Pacific and employs about 8,000 employees worldwide. Sysmex Corporation is listed in the top tier of the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit http://www.sysmex.co.jp/en/.